WVE

Wave Life Sciences

WVE

Attention (50-day avg)0%

Attention rank (50-day avg)#1,469

Bullish sentiment (50-day avg)41%

Price to earnings ratio-3.02

Market capitalization723.2M

Earnings per share-1.05

Dividend yield (TTM)—

Revenue (annual)42.7M

Net income (annual)-204.4M

Social

What share of all stock conversation is about WVE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% +0	0% 0

Sep 23

Wave Life Sciences Ltd. initiates Phase 2a combination trial of WVE-007 (GalNAc-siRNA) with tirzepatide for obesity.
JPMorgan resumes coverage of Wave Life Sciences with a Neutral rating, citing the need for convincing efficacy data, including at least 5% weight loss alongside improvements in body composition and metabolic risk factors.
Wave Life Sciences' WVE-007 is the key driver of upside according to JPMorgan, but the bank wants to see more data before becoming more bullish on the stock.

Generated by AI

Sentiment

Of the messages about WVE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	25%	25% -25	48.57% +11.9	61.06% -25.43
Bearish	75%	75% +25	51.43% -11.9	38.94% +25.43

Bullish· Jul 17

Wave Life Sciences Ltd. ($WVE) has a high potential for growth, with the possibility of doubling in value within the next 6-12 months.
A WhatsApp group has been created to provide real-time updates on stock news and trends, with $WVE among the recommended stocks.
The stock's price may rise due to its high-quality nature, as recommended by the WhatsApp group.

Bearish· Mar 26

The company's obesity therapy, WVE-007, showed minimal weight loss, with patients only losing 14.3% of visceral fat mass in 6 months, raising doubts about the effectiveness of the treatment.
The recent data from Wave Life Sciences' obesity therapy program has put a huge question mark on RNA as a valid therapeutic modality, making it difficult for the company to continue the program.
The stock price has plummeted, losing over 50% of its value, and experts are questioning whether the company can recover, with one analyst lowering the price target to $18 from $28.

Generated by AI

Topics

Of the messages about WVE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	96.24%	22.89%
Technical Analysis	—	50%	1.08%	26.77%
Analysts	—	50%	2.69%	27.9%
Earnings	—	0%	0%	0.31%
Controversies	—	0%	0%	0.21%
Macro	—	0%	0%	21.92%

Analysts· Dec 31

Wave Life Sciences ($WVE) was downgraded to Market Perform from Outperform at Leerink with a price target of $10.
Mizuho upgraded Wave Life Sciences ($WVE) to a price target of $65.00.
Analysts set Wave Life Sciences Ltd ($WVE) target price at $37.50, and SunTrust Banks cut the price target to $20.00.

Announcements· Mar 27

Wave Life Sciences Ltd. (WVE) faces pressure to prove the efficacy of its Botox endpoints, particularly in the post-GLP1 setting.
WVE's share price drop has made it a potential takeover target, with GlaxoSmithKline (GSK) CEO looking to acquire companies worth $2B to $4B.
WVE is expected to present P1 obesity results for INHBE in YE26, which could lead to intraday volatility and spark market interest in the company's gene editing treatments for neurodegenerative and cardiovascular diseases.

Technical Analysis· Dec 11

$WVE's price is rising, but insiders are selling, which could be a sign of weakness.
Wave Life Sciences Ltd.'s management sold $17M worth of shares, which could be a bearish signal, but the company's 10b5-1 plan may have contributed to the sale.
The stock's 5-minute chart has formed a rejection, which could be a bearish sign, and the 1-minute chart is showing an oversold area, which could be a sign of a potential bounce back.

Generated by AI

Community

Of the messages about WVE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	15.38%	60%	86.79%	49.11%
Newcomers	84.62%	40%	13.21%	50.89%

Regulars· Mar 31

RA Capital Management, a significant shareholder, has increased its stake in Wave Life Sciences Ltd. by 61% and made a $54.6M insider buy, purchasing 8,772,496 shares at $6.23 per share.
The company's RNA editing technology is seen as less convenient and less effective compared to base editing, which has sparked skepticism among enthusiasts.
A director, Rajeev M. Shah, purchased 8,772,496 shares at an average price of $6.23, making it a notable insider buy.

Newcomers· Jul 17

The newcomers are focusing on the potential rise of Wave Life Sciences Ltd. ($WVE) as they recommend it along with other stocks, indicating a bullish sentiment.
The newcomers are creating a WhatsApp group for stock investors to join and receive daily real-time updates on stock news and trends, suggesting a desire for community and information sharing.
The newcomers are recommending Wave Life Sciences Ltd. ($WVE) as one of the stocks that may rise, indicating a focus on the company's potential for growth and increased value.

Generated by AI

News

Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Cantor 2026 Global Healthcare Conference in New York City on Thursday, September 10, 2026 at 9:45 a.m. ET. A live webcast of the present

26d agoYahoo Finance

Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover

Wave Life Sciences has lost nearly 70% of its value this year, yet its RNA platform spans obesity, rare liver disease, and genetic disorders in ways that could make it irresistible to the right buyer. The question is which pharma giant moves first.

1mo agoYahoo Finance

Also Discussed

Investors talking about WVE also mention

#	Name	Attention
1	TERN - Terns Pharmaceuticals, Inc.	——
2	ProQR Therapeutics N.V. Ordinary SharesPRQR	0%0
3	Structure Therapeutics Inc. American Depositary SharesGPCR	0%new
4	Arrowhead Pharmaceuticals, Inc.ARWR	0%+0
5	uniQure N.V.QURE	0.02%+0.01
6	Regenxbio Inc.RGNX	0%+0
7	Janux Therapeutics, Inc.JANX	0%0
8	MTSR - Metsera, Inc.	——
9	Solid Biosciences Inc.SLDB	0.3%new
10	Abivax SAABVX	0.01%-0.01

Wave Life Sciences Ltd.

Healthcare
Biotechnology

Wave Life Sciences Ltd. is a biotechnology company focused on unlocking the potential of RNA medicines, specifically oligonucleotides targeting ribonucleic acid to transform human health. It leverages its proprietary PRISM platform, which integrates multiple RNA-targeting modalities such as RNA editing, splicing, antisense silencing, and RNA interference, along with chemistry innovation and insights from human genetics. This enables the development of first- or best-in-class therapeutics for both rare and prevalent disorders. The company's pipeline features clinical programs addressing Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington’s disease, as well as preclinical efforts in obesity. These initiatives target diseases originating in the liver, muscle, central nervous system, and other tissues, aiming to deliver disease-modifying therapies with life-changing potential. Founded in 2012 and headquartered in Cambridge, Massachusetts, with operations in Singapore, Wave Life Sciences Ltd. plays a key role in advancing precision medicine for genetic conditions through innovative RNA-based approaches.

Website

Location

733 Concord Avenue

Cambridge, MA, 02138

United States

Social

What share of all stock conversation is about WVE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% +0	0% 0

Sep 23

Wave Life Sciences Ltd. initiates Phase 2a combination trial of WVE-007 (GalNAc-siRNA) with tirzepatide for obesity.
JPMorgan resumes coverage of Wave Life Sciences with a Neutral rating, citing the need for convincing efficacy data, including at least 5% weight loss alongside improvements in body composition and metabolic risk factors.
Wave Life Sciences' WVE-007 is the key driver of upside according to JPMorgan, but the bank wants to see more data before becoming more bullish on the stock.

Generated by AI

Sentiment

Of the messages about WVE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	25%	25% -25	48.57% +11.9	61.06% -25.43
Bearish	75%	75% +25	51.43% -11.9	38.94% +25.43

Bullish· Jul 17

Wave Life Sciences Ltd. ($WVE) has a high potential for growth, with the possibility of doubling in value within the next 6-12 months.
A WhatsApp group has been created to provide real-time updates on stock news and trends, with $WVE among the recommended stocks.
The stock's price may rise due to its high-quality nature, as recommended by the WhatsApp group.

Bearish· Mar 26

The company's obesity therapy, WVE-007, showed minimal weight loss, with patients only losing 14.3% of visceral fat mass in 6 months, raising doubts about the effectiveness of the treatment.
The recent data from Wave Life Sciences' obesity therapy program has put a huge question mark on RNA as a valid therapeutic modality, making it difficult for the company to continue the program.
The stock price has plummeted, losing over 50% of its value, and experts are questioning whether the company can recover, with one analyst lowering the price target to $18 from $28.

Generated by AI

Topics

Of the messages about WVE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	96.24%	22.89%
Technical Analysis	—	50%	1.08%	26.77%
Analysts	—	50%	2.69%	27.9%
Earnings	—	0%	0%	0.31%
Controversies	—	0%	0%	0.21%
Macro	—	0%	0%	21.92%

Analysts· Dec 31

Wave Life Sciences ($WVE) was downgraded to Market Perform from Outperform at Leerink with a price target of $10.
Mizuho upgraded Wave Life Sciences ($WVE) to a price target of $65.00.
Analysts set Wave Life Sciences Ltd ($WVE) target price at $37.50, and SunTrust Banks cut the price target to $20.00.

Announcements· Mar 27

Wave Life Sciences Ltd. (WVE) faces pressure to prove the efficacy of its Botox endpoints, particularly in the post-GLP1 setting.
WVE's share price drop has made it a potential takeover target, with GlaxoSmithKline (GSK) CEO looking to acquire companies worth $2B to $4B.
WVE is expected to present P1 obesity results for INHBE in YE26, which could lead to intraday volatility and spark market interest in the company's gene editing treatments for neurodegenerative and cardiovascular diseases.

Technical Analysis· Dec 11

$WVE's price is rising, but insiders are selling, which could be a sign of weakness.
Wave Life Sciences Ltd.'s management sold $17M worth of shares, which could be a bearish signal, but the company's 10b5-1 plan may have contributed to the sale.
The stock's 5-minute chart has formed a rejection, which could be a bearish sign, and the 1-minute chart is showing an oversold area, which could be a sign of a potential bounce back.

Generated by AI

Community

Of the messages about WVE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	15.38%	60%	86.79%	49.11%
Newcomers	84.62%	40%	13.21%	50.89%

Regulars· Mar 31

RA Capital Management, a significant shareholder, has increased its stake in Wave Life Sciences Ltd. by 61% and made a $54.6M insider buy, purchasing 8,772,496 shares at $6.23 per share.
The company's RNA editing technology is seen as less convenient and less effective compared to base editing, which has sparked skepticism among enthusiasts.
A director, Rajeev M. Shah, purchased 8,772,496 shares at an average price of $6.23, making it a notable insider buy.

Newcomers· Jul 17

The newcomers are focusing on the potential rise of Wave Life Sciences Ltd. ($WVE) as they recommend it along with other stocks, indicating a bullish sentiment.
The newcomers are creating a WhatsApp group for stock investors to join and receive daily real-time updates on stock news and trends, suggesting a desire for community and information sharing.
The newcomers are recommending Wave Life Sciences Ltd. ($WVE) as one of the stocks that may rise, indicating a focus on the company's potential for growth and increased value.

Generated by AI

Wave Life Sciences

Social

Sep 23

Bullish· Jul 17

Bearish· Mar 26

Analysts· Dec 31

Announcements· Mar 27

Technical Analysis· Dec 11

Regulars· Mar 31

Newcomers· Jul 17

Wave Life Sciences starts Phase 2a obesity trial for WVE-007

JPMorgan resumes Wave Life Sciences stock rating at Neutral

Wave Life Sciences appoints Monika Vnuk as chief business officer

Wave Life Sciences at Cantor conference: RNA editing gains traction

Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference

Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover

Also Discussed

Wave Life Sciences Ltd.

Company Information

Location

Wave Life Sciences starts Phase 2a obesity trial for WVE-007

JPMorgan resumes Wave Life Sciences stock rating at Neutral

Wave Life Sciences appoints Monika Vnuk as chief business officer

Wave Life Sciences at Cantor conference: RNA editing gains traction

Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference

Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover

Also Discussed

Social

Sep 23

Bullish· Jul 17

Bearish· Mar 26

Analysts· Dec 31

Announcements· Mar 27

Technical Analysis· Dec 11

Regulars· Mar 31

Newcomers· Jul 17